Victory Capital Management Inc. Has $10.07 Million Stake in Diplomat Pharmacy Inc (DPLO)

Victory Capital Management Inc. trimmed its position in Diplomat Pharmacy Inc (NYSE:DPLO) by 19.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 501,600 shares of the company’s stock after selling 123,960 shares during the quarter. Victory Capital Management Inc. owned about 0.73% of Diplomat Pharmacy worth $10,067,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of DPLO. Schwab Charles Investment Management Inc. raised its stake in Diplomat Pharmacy by 40.4% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 230,013 shares of the company’s stock valued at $3,405,000 after purchasing an additional 66,244 shares during the last quarter. Ameriprise Financial Inc. raised its stake in Diplomat Pharmacy by 19.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 272,979 shares of the company’s stock valued at $4,043,000 after purchasing an additional 44,135 shares during the last quarter. Nationwide Fund Advisors raised its stake in Diplomat Pharmacy by 253.5% during the 2nd quarter. Nationwide Fund Advisors now owns 106,500 shares of the company’s stock valued at $1,576,000 after purchasing an additional 76,376 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Diplomat Pharmacy by 46.7% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after purchasing an additional 2,794 shares during the last quarter. Finally, New York State Common Retirement Fund raised its stake in Diplomat Pharmacy by 11.4% during the 2nd quarter. New York State Common Retirement Fund now owns 52,900 shares of the company’s stock valued at $783,000 after purchasing an additional 5,399 shares during the last quarter. Institutional investors and hedge funds own 69.34% of the company’s stock.

Several equities analysts recently commented on the stock. Deutsche Bank cut shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating and upped their target price for the company from $22.00 to $29.00 in a research note on Friday, February 2nd. Robert W. Baird cut shares of Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and cut their target price for the company from $24.00 to $18.00 in a research note on Thursday, November 16th. Lake Street Capital assumed coverage on shares of Diplomat Pharmacy in a research note on Friday, February 9th. They set a “buy” rating and a $35.00 target price for the company. Credit Suisse Group upgraded shares of Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and set a $28.00 target price for the company in a research note on Thursday, January 25th. Finally, Mizuho set a $16.00 target price on shares of Diplomat Pharmacy and gave the company a “hold” rating in a research note on Tuesday, October 24th. Seven research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Diplomat Pharmacy presently has a consensus rating of “Buy” and a consensus price target of $23.95.

Shares of Diplomat Pharmacy Inc (DPLO) opened at $23.81 on Friday. The stock has a market cap of $1,640.00, a price-to-earnings ratio of 198.42 and a beta of 1.05. The company has a quick ratio of 0.82, a current ratio of 1.34 and a debt-to-equity ratio of 0.18. Diplomat Pharmacy Inc has a fifty-two week low of $13.39 and a fifty-two week high of $27.78.

In other Diplomat Pharmacy news, CFO Atul Kavthekar purchased 2,000 shares of the stock in a transaction on Monday, November 20th. The shares were purchased at an average price of $15.00 per share, with a total value of $30,000.00. Following the acquisition, the chief financial officer now directly owns 2,000 shares of the company’s stock, valued at approximately $30,000. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Jeffrey G. Park purchased 3,000 shares of the stock in a transaction on Monday, November 20th. The stock was acquired at an average cost of $15.46 per share, for a total transaction of $46,380.00. Following the acquisition, the director now directly owns 7,640 shares in the company, valued at $118,114.40. The disclosure for this purchase can be found here. Insiders acquired a total of 15,000 shares of company stock worth $228,780 in the last three months. Insiders own 30.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Victory Capital Management Inc. Has $10.07 Million Stake in Diplomat Pharmacy Inc (DPLO)” was reported by Week Herald and is the property of of Week Herald. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://weekherald.com/2018/02/16/victory-capital-management-inc-has-10-07-million-stake-in-diplomat-pharmacy-inc-dplo.html.

Diplomat Pharmacy Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc (NYSE:DPLO).

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply